Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy
Cet article, intitulé « Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy », est une étude observationnelle rétrospective publiée en juillet 2024 dans la revue « ESC Heart Failure ». Voici les principaux points à retenir : Objectif de l’étude : Caractériser les troubles cardiaques et extracardiaques au moment du diagnostic Évaluer le pronostic des […]
Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome.
Dr Lise LEGRAND – Cardiologue APHP Pitié Salpêtrière – Paris Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. https://pubmed.ncbi.nlm.nih.gov/36049804/ PMID : 36049804
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Dr Benjamin ALOS – Cardiologue CHU de Poitiers Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/35999650/ PMID : 35999650
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Dr Julien JEANNETEAU – Cardiologue Clinique St Joseph – Trélazé Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34994254/ PMID : 34994254
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Dr Marc-Antoine DELBARRE – Médecin Interniste CHU Amiens Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. https://pubmed.ncbi.nlm.nih.gov/35908242/ PMID : 35908242
Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis.
Dr Damien LEGALLOIS – Cardiologue CHU de Caen Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35861981/ PMID : 35861981
Characteristics and natural history of early-stage cardiac transthyretin amylo
Dr Arnaud GALAT – Cardiologue – Hopital Prive Paul D’Egine – Champigny-sur-Marne Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35608040/ PMID : 35608040
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
Dr Olivier HUTTIN – Cardiologue CHU de Nancy Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35779241/ PMID : 35779241
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.
Dr Amira ZAROUI – Cardiologue APHP Henri Mondor – Créteil Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. https://pubmed.ncbi.nlm.nih.gov/31189919/ PMID : 31189919
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Dr Anne-Catherine POULEUR : Cardiologue – institut cardiovasculaire Saint Luc – Bruxelles BELGIQUE